标题
Perspectives on chemotherapy for the management of double-hit lymphoma
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-9
出版商
Informa UK Limited
发表日期
2020-02-18
DOI
10.1080/14656566.2020.1727445
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma
- (2020) Jad Othman et al. BONE MARROW TRANSPLANTATION
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
- (2019) Stephen M. Ansell et al. JOURNAL OF CLINICAL ONCOLOGY
- Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
- (2019) Kamal Chamoun et al. Journal of Hematology & Oncology
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
- (2019) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Choosing the right pharmacotherapy for non-Hodgkin’s lymphoma: does one size fit all?
- (2019) Taha Al Juhaishi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity
- (2019) Abdullah Alsuwaidan et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
- (2019) Andrew D. Zelenetz et al. BLOOD
- Diffuse Large B cell Lymphoma: 2019 update on diagnosis, risk-stratification and treatment
- (2019) Yang Liu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium
- (2019) Andreas Rosenwald et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
- (2019) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Poor outcomes for double‐hit lymphoma patients treated with curative‐intent second‐line immunochemotherapy following failure of intensive front‐line immunochemotherapy
- (2019) Daniel J. Landsburg et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial
- (2019) Martine E.D. Chamuleau et al. HAEMATOLOGICA
- Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma)
- (2018) Dongfeng Zeng et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma
- (2018) Alex F. Herrera et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy
- (2018) Vasu Tumati et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
- (2018) Matthew J. Maurer et al. JOURNAL OF CLINICAL ONCOLOGY
- Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
- (2018) Howard A Burris et al. LANCET ONCOLOGY
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
- (2018) Bjoern Chapuy et al. NATURE MEDICINE
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary Refractory Double Hit Diffuse Large B Cell Lymphoma: Complete Response with Ibrutinib and Rituximab
- (2018) Arnav Sethi et al. Clinical Lymphoma Myeloma & Leukemia
- PLK1: a promising and previously unexplored target in double-hit lymphoma
- (2018) Quais N. Hassan et al. JOURNAL OF CLINICAL INVESTIGATION
- Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation
- (2018) Andrea Clocchiatti et al. JOURNAL OF CLINICAL INVESTIGATION
- Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
- (2018) Daisuke Ennishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations
- (2018) George Daniel Grass et al. LEUKEMIA & LYMPHOMA
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
- (2018) Kieron Dunleavy et al. Lancet Haematology
- Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB
- (2017) Lauren A. Solomon et al. EXPERIMENTAL HEMATOLOGY
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies
- (2016) Changchun Deng et al. BLOOD
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era
- (2016) Santosha A. Vardhana et al. BRITISH JOURNAL OF HAEMATOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities
- (2015) A. Kritharis et al. BLOOD
- MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study
- (2015) C. Copie-Bergman et al. BLOOD
- Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis
- (2015) Christina Howlett et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
- (2014) A. M. Petrich et al. BLOOD
- A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma
- (2014) C Y Cheah et al. BRITISH JOURNAL OF CANCER
- Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival
- (2014) Jonathon B. Cohen et al. CANCER
- MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations
- (2013) Mette Ø. Pedersen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
- (2012) W. Cuccuini et al. BLOOD
- Allogeneic Transplantation for Lymphoma
- (2011) Ronjon Chakraverty et al. JOURNAL OF CLINICAL ONCOLOGY
- Double-hit B-cell lymphomas
- (2010) S. M. Aukema et al. BLOOD
- Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era
- (2010) Marita Ziepert et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- (2008) Peter H. Wiernik et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More